Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age

This study assesses the safety and efficacy of repeat monthly dosing of super-selective intra-arterial cerebral infusion (SIACI) of cetuximab and bevacizumab in patients \< 22 years of age.

Trial Details

NCT ID
NCT05956821
Phase
PHASE1 / PHASE2
Sponsor
University of Miami
Status
RECRUITING
Cancer Type
Brain Cancer
Interventions
  • SIACI of cetuximab and bevacizumab
Locations (sample)
  • Miami, Florida, United States|25.77427,-80.19366

Key Eligibility Criteria

  • Documented histologic diagnosis of relapsed or refractory glioblastoma multiforme (GBM), anaplastic astrocytoma (AA), fibrillary astrocytomas (FA),…
  • Must have at least one confirmed and evaluable tumor site
  • Must have a Karnofsky or Lansky performance status ≥60%.
  • No chemotherapy for three weeks prior to treatment

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Brain Cancer Trials on Trialify →